Solid Biosciences up after FDA nod for gene therapy trial

Solid Biosciences

14/11/2023 21:58

** Shares of genetic-muscle disorder drug developer Solid
Biosciences  SLDB.O  rise 29.8% to $2.76 after-market
    ** Co says U.S. Food and Drug Administration has cleared its
Investigational New Drug (IND), allowing it begin a clinical
trial for its gene therapy candidate SGT-003 
    ** SLDB will evaluate SGT-003 as a potential treatment for
Duchenne Muscular Dystrophy (DMD), a progressive muscle-wasting
disorder
    ** SLDB plans to begin an early-stage study of the therapy
in DMD patients aged 4 to under 6 years
    ** YTD, Solid Biosciences shares down 60.4%

 (Reporting by Abhinav Parmar and Bhanvi Satija in Bengaluru)
 ((abhinav.parmar@thomsonreuters.com))